Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Zuo, Xiangsheng ^a   Xu, Min ^a   Yu, Jiang ^a   Wu, Yuanqing ^a   Moussalli, Micheline J ^a   Manyam, Ganiraju C ^a   Lee, Sun Il ^b   Liang, Shoudan ^a   Gagea, Mihai ^a   Morris, Jeffrey S ^a   Broaddus, Russell R ^a   Shureiqi, Imad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TRANSCRIPTOME; CARCINOGEN; CELL RECEPTOR; PPARD PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; COLON CANCER; CONTROLLED STUDY; DUODENUM MUCOSA; EPITHELIUM HYPERPLASIA; GENE DELETION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC SUSCEPTIBILITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE MUCOSA; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DISEASE PREDISPOSITION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM;

ANIMALS; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; DISEASE SUSCEPTIBILITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PPAR-BETA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; UP-REGULATION;

EID: 84898865037     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju052     Document Type: Article

References (39)

1. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004;4(1):61-70.
2. Choi YJ, Roberts BK, Wang X, et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012;220(2):470-476.
3. Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome prolifer-ator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332-339.
4. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12(3):181-195.
5. He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99(3):335-345.
6. Gupta RA, Ta n J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA. 2000;97(24):13275-13280.
7. Yoshinaga M, Kitamura Y, Chaen T, et al. The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorec-tal cancers. Dig Dis Sci. 2009;54(5):1108-1114.
8. Yoshinaga M, Taki K, Somada S, et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci. 2011;56(4):1194-1200.
9. Delage B, Rullier A, Capdepont M, et al. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutrition J. 2007;6(1):20.
10. Takayama O, Yamamoto H, Damdinsuren B, et al. Expression of PPAR[delta] in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Brit J Cancer. 2006;95(7):889-895.
11. Knutsen HK, Olstorn HB, Paulsen JE, et al. Increased levels of PPARβ/δ and cyclin D1 in flat dysplastic ACF and adenomas in ApcMin/+ mice. Anticancer Res. 2005;25(6B):3781-3789.
12. Zuo X, Peng Z, Moussalli MJ, et al. Targeted Genetic disruption of peroxi-some proliferator-activated receptor-{delta} and colonic tumorigenesis. J Natl Cancer Inst. 2009;101(10):762-767.
13. Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator- activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA. 2002;99(1):303-308.
14. Harman FS, Nicol CJ, Marin HE, et al. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med. 2004;10(5):481-483.
15. Wang D, Wang H, Guo Y, et al. Crosstalk between peroxisome prolifera-tor-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci USA. 2006;103(50):19069-19074.
16. Madison BB, Braunstein K, Kuizon E, et al. Epithelial hedgehog signals pattern the intestinal crypt-villus axis. Development. 2005;132(2):279-289.
17. Zuo X, Peng Z, Wu Y, et al. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst. 2012;104(9):709-716.
18. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics. 2003;19(10):1236-1242.
19. Nadra K, Anghel SI, Joye E, et al. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor {beta}/{delta}. Mol Cell Biol. 2006;26(8):3266-3281.
20. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protocols. 2007;2(8):1998-2004.
21. Nambiar PR, Girnun G, Lillo NA, et al. Preliminary analysis of azoxym-ethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol. 2003;22(1):145-150.
22. Wu Ya, Wang X, Wu F, et al. Transcriptome profiling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. PLoS One. 2012;7(8):e41001.
23. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
24. Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer. 2008;8(6):415-424.
25. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):3-8.
26. Genetics Home Reference. In: US National Library of Medicine. http://ghr.nlm.nih.gov/. Accessed September 2013.
27. Stove C, Bracke M. Roles for neuregulins in human cancer. Clin Exp Metastasis. 2005;21(8):665-684.
28. Venkateswarlu S, Dawson DM, St Clair P, et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene. 2002;21(1):78-86.
29. Tanaka SS, Matsui Y. Developmentally regulated expression of mil-1 and mil-2, mouse interferon-induced transmembrane protein like genes, during formation and differentiation of primordial germ cells. Mech Devel. 2002;119(Suppl):S261-S267.
30. Saitou M, Barton SC, Surani MA. A molecular programme for the specification of germ cell fate in mice. Nature. 2002;418(6895):293-300.
31. Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genom-ewide gene-expression analyses. Cancer. 2008;113(2):266-275.
32. Andreu P, Colnot S, Godard C, et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res. 2006;66(4):1949-1955.
33. Li D, Peng Z, Tang H, et al. KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin Cancer Res. 2011;17(11):3558-3568.
34. Barthold SW, Beck D. Modification or early dimethylhydrazine carcino-genesis by colonic mucosal hyperplasia. Cancer Res. 1980;40(12):4451- 4455.
35. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA. 2002;99(5):2613-2618.
36. Jin H, Wang X, Ying J, et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esopha-geal, nasopharyngeal and multiple other carcinomas. Oncogene. 2007;26(53):7490-7498.
37. Petrova T V, Nykänen A, Norrmén C, et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell. 2008;13(5):407-419.
38. Chen J, Kwong DL-W, Zhu C-L, et al. RBMS3 at 3p24 inhibits naso-pharyngeal carcinoma development via inhibiting cell proliferation, angio-genesis, and inducing apoptosis. PLoS One. 2012;7(9):e44636.
39. El-Tanani M, Barraclough R, Wilkinson MC, et al. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res. 2001;61(14):5619-5629.